GEM05 for Patients With Multiple Myeloma Under 65 Years
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare safety and efficacy of three induction treatments:
VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide /
Dexamethasone. The second one is to evaluate the ability of stem cell mobilization after the
treatments in order to do an autologous transplant. Otherwise this study wants to compare the
safety and efficacy of the maintenance treatments: Interferón a-2b versus Thalidomide versus
Thalidomide/Velcade.